Evaluation of methotrexate and cyclosporine for severe psoriasis: A retrospective analysis from tertiary hospital in Indonesia

Authors

  • Menul Ayu Umborowati Department of Dermatology and Venerology, Faculty of Medicine Universitas Airlangga/Dr. Soetomo Hospital, Surabaya, Indonesia Array (unauthenticated)
  • Made Putri Hendaria Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Sylvia Anggraeni Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Irmadita Citrashanty Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Damayanti Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Afif Nurul Hidayati Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Anang Endaryanto Department of Child Health, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)
  • Ingrid S Surono Food Technology Department Faculty of Engineering, Bina Nusantara University, Jakarta, Indonesia Array (unauthenticated)
  • Cita Rosita Sigit Prakoeswa Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia Array (unauthenticated)

DOI:

https://doi.org/10.66344/jpad.33.1.2023.1997

Abstract

Background Psoriasis is an autoimmune disease manifested as chronic, recurrent thick red scaly plaques. Cyclosporine and methotrexate have been used as therapy for severe psoriasis since decades. This study aims to evaluate the clinical outcome of methotrexate and cyclosporine as treatment for severe psoriasis.

 

Methods A three-year retrospective analysis was undertaken to examine the medical records of hospitalized patients with severe psoriasis. This study evaluated outcomes such as psoriasis area and severity index (PASI) and length of hospital stay (LOS).

 

Results Twenty-six patients were included in the study. Mean PASI reduction was 42.8% (± 24.64), with greater reduction in cyclosporine group (mean 54.88±12.73%) than that in methotrexate group (mean 43.22±24.4%). Patients in cyclosporine group stayed longer (18.83±9.39 days) than patients in methotrexate group (11.65±5.91 days).

 

Conclusion Methotrexate and cyclosporine treatment are effective for severe psoriasis. However, the hospital stays for patients receiving cyclosporine treatment might be longer.

Author Biography

  • Made Putri Hendaria, Faculty of Medicine, Universitas Airlangga, Indonesia

    Department of Dermatology and Venereology

Downloads

Published

05.03.2023

Issue

Vol. 33 No. 1 (2023): January-March

Section

Original Articles

License

Copyright (c) 2023 Menul Ayu Umborowati, Made Putri Hendaria, Sylvia Anggraeni, Irmadita Citrashanty, Damayanti, Afif Nurul Hidayati, Anang Endaryanto, Ingrid S Surono, Cita Rosita Sigit Prakoeswa

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

How to Cite

1.
Evaluation of methotrexate and cyclosporine for severe psoriasis: A retrospective analysis from tertiary hospital in Indonesia. J Pak Assoc Dermatol [Internet]. 2023 Mar. 5 [cited 2026 Jul. 22];33(1):3-8. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1997